Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma

Targeted Oncology
Hannah A Blair, Greg L Plosker

Abstract

Sorafenib (Nexavar®) is the first tyrosine kinase inhibitor to be approved for the treatment of radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC). In the pivotal phase III DECISION trial in patients with RAI-refractory, locally advanced or metastatic DTC, oral sorafenib 400 mg twice daily significantly prolonged median progression-free survival (PFS) relative to placebo. The PFS benefit of sorafenib over placebo was evident in all pre-specified clinical and genetic biomarker subgroups, and neither BRAF nor RAS mutation status was predictive of sorafenib benefit for PFS. The objective response rate was significantly higher in patients receiving sorafenib than in those receiving placebo; all objective responses were partial responses. The overall survival benefit of sorafenib is as yet unclear, with no significant benefit observed at the time of primary analysis or at 9 months following the primary analysis. Overall survival was possibly confounded by the crossover of patients in the placebo group to sorafenib upon disease progression. The adverse events associated with sorafenib in the DECISION trial were consistent with the known tolerability profile of the drug, with hand-foot skin reaction, diarrhea, ...Continue Reading

References

Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Jun 11, 2005·Endocrine-related Cancer·M Xing
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey W ClarkHeinz-Josef Lenz
Sep 1, 2005·Cancer Chemotherapy and Pharmacology·Chetan LathiaPavur Sundaresan
May 27, 2006·European Journal of Endocrinology·Furio PaciniUNKNOWN European Thyroid Cancer Taskforce
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley
Nov 28, 2006·Biochimica Et Biophysica Acta·James A McCubreyRichard A Franklin
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vandana Gupta-AbramsonMarcia S Brose
Feb 21, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nilofer S AzadHeidi H Kong
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard T KloosManisha H Shah
Oct 29, 2009·Thyroid : Official Journal of the American Thyroid Association·UNKNOWN American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerR Michael Tuttle
May 14, 2011·European Journal of Endocrinology·Merina AhmedChristopher M Nutting
Apr 25, 2012·Journal of Thyroid Research·Naifa Lamki Busaidy, Maria E Cabanillas
Feb 26, 2013·Current Opinion in Otolaryngology & Head and Neck Surgery·Iain J NixonMichael R Tuttle
Jul 3, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Poupak FallahiAlessandro Antonelli
Oct 16, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Wendy Sacks, Glenn D Braunstein
Nov 19, 2013·Current Opinion in Oncology·Sigurdis Haraldsdottir, Manisha H Shah
Dec 5, 2013·Endocrine-related Cancer·Chen-Tian ShenQuan-Yong Luo
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Feb 25, 2014·The Oncologist·Ligy ThomasMaria E Cabanillas
Apr 15, 2014·Arquivos brasileiros de endocrinologia e metabologia·Fabian Pitoia
Jul 24, 2014·OncoTargets and Therapy·Daniel C McFarland, Krzysztof J Misiukiewicz
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·ZhengGang RenSheng-Long Ye

❮ Previous
Next ❯

Citations

Feb 20, 2018·Molecular Cancer·Qinlian JiaoYun-Shan Wang
Feb 23, 2018·Cell Death & Disease·Emira AyroldiCarlo Riccardi
Dec 3, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Heinz HammerlindlHelmut Schaider

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.